Cargando…
Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
Aim: The aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with inter...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107235/ https://www.ncbi.nlm.nih.gov/pubmed/25057310 http://dx.doi.org/10.7150/jca.9413 |
_version_ | 1782327569350131712 |
---|---|
author | Nishikawa, Hiroki Kita, Ryuichi Kimura, Toru Ohara, Yoshiaki Takeda, Haruhiko Sakamoto, Azusa Saito, Sumio Nishijima, Norihiro Nasu, Akihiro Komekado, Hideyuki Osaki, Yukio |
author_facet | Nishikawa, Hiroki Kita, Ryuichi Kimura, Toru Ohara, Yoshiaki Takeda, Haruhiko Sakamoto, Azusa Saito, Sumio Nishijima, Norihiro Nasu, Akihiro Komekado, Hideyuki Osaki, Yukio |
author_sort | Nishikawa, Hiroki |
collection | PubMed |
description | Aim: The aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with intermediate HCC undergoing TACE. Methods: Clinical outcomes, including overall survival (OS) and tumor response rate at initial therapy, were compared between these two groups. Results: The median survival time and the 1- and 3-year cumulative OS rates were 2.90 years and 84.1% and 48.0%, respectively, in the elderly group and 2.44 years and 78.2% and 39.3%, respectively, in the control group (p=0.887). The objective response rate in the elderly group was 81.8% (54/66 patients), while that in the control group was 78.6% (66/84 patients) (p=0.227). Conclusion: Elderly patients with intermediate HCC undergoing TACE had a prognosis comparable with that of younger patients with intermediate HCC undergoing TACE. |
format | Online Article Text |
id | pubmed-4107235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-41072352014-07-23 Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients Nishikawa, Hiroki Kita, Ryuichi Kimura, Toru Ohara, Yoshiaki Takeda, Haruhiko Sakamoto, Azusa Saito, Sumio Nishijima, Norihiro Nasu, Akihiro Komekado, Hideyuki Osaki, Yukio J Cancer Research Paper Aim: The aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with intermediate HCC undergoing TACE. Methods: Clinical outcomes, including overall survival (OS) and tumor response rate at initial therapy, were compared between these two groups. Results: The median survival time and the 1- and 3-year cumulative OS rates were 2.90 years and 84.1% and 48.0%, respectively, in the elderly group and 2.44 years and 78.2% and 39.3%, respectively, in the control group (p=0.887). The objective response rate in the elderly group was 81.8% (54/66 patients), while that in the control group was 78.6% (66/84 patients) (p=0.227). Conclusion: Elderly patients with intermediate HCC undergoing TACE had a prognosis comparable with that of younger patients with intermediate HCC undergoing TACE. Ivyspring International Publisher 2014-07-17 /pmc/articles/PMC4107235/ /pubmed/25057310 http://dx.doi.org/10.7150/jca.9413 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Nishikawa, Hiroki Kita, Ryuichi Kimura, Toru Ohara, Yoshiaki Takeda, Haruhiko Sakamoto, Azusa Saito, Sumio Nishijima, Norihiro Nasu, Akihiro Komekado, Hideyuki Osaki, Yukio Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients |
title | Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients |
title_full | Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients |
title_fullStr | Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients |
title_full_unstemmed | Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients |
title_short | Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients |
title_sort | transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107235/ https://www.ncbi.nlm.nih.gov/pubmed/25057310 http://dx.doi.org/10.7150/jca.9413 |
work_keys_str_mv | AT nishikawahiroki transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT kitaryuichi transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT kimuratoru transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT oharayoshiaki transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT takedaharuhiko transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT sakamotoazusa transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT saitosumio transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT nishijimanorihiro transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT nasuakihiro transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT komekadohideyuki transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients AT osakiyukio transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients |